Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

I am a 73-year-old man who has recently been diagnosed with moderate-to-severe arthritis in my right knee. I am trying to figure out a healthy way to ...

Following Keytruda, Bristol-Myers Squibb (BMS) and Pfizer's Eliquis (apixaban), an oral anticoagulant, will be the second best-selling drug out of the top ten, with annual sales of $18.7 billion ...

The OCEANIC-AF is comparing asundexian to Pfizer and Bristol-Myers Squibb’s widely-used oral Factor Xa inhibitor Eliquis (apixaban) in AF patients at risk of a stroke, to see how well they ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial ...

A senior official of the Pharmexcil said drugs such as Merck's Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-Myers Squibb's Eliquis (Apixaban)-USD 12 billion, among others ...